Company Filing History:
Years Active: 1996-1998
Title: Inventor Profile: Chun Hee Chung
Introduction
Chun Hee Chung, a prominent inventor based in Seoul, South Korea, has made significant contributions to the field of biotechnology, particularly in the development of innovative strains that hold potential therapeutic applications. With a total of two patents to his name, his research focuses on harnessing the properties of Ganoderma lucidum, a fungus known for its medicinal benefits.
Latest Patents
Chung's latest patent, titled "Ganoderma lucidum KCCM 10045," is centered around a unique strain known as Ganoderma lucidum IY 009. This strain is notable for its capability to produce proteoglycan (G009), which demonstrates antitumoral and immunostimulating effects. The proteoglycan consists of saccharide components such as beta-glucose, alpha-glucose, galactose, alpha-mannose, and fructose. Additionally, it contains essential protein components, including glycine, alanine, histidine, arginine, and several others. The strain Ganoderma lucidum IY 009 has been deposited under the accession number KCCM 10045, marking a significant step forward in cancer immunotherapy.
Career Highlights
Chun Hee Chung is currently associated with Il Yang Pharmaceutical Company, Ltd., where he continues to develop groundbreaking solutions in the realm of pharmaceuticals and biotechnology. His work within this company highlights his commitment to advancing medical research and innovation.
Collaborations
Chung's research efforts are further enhanced by collaborations with talented colleagues, including Kwon Haeng Lee and Hoon Chung. Working alongside these skilled professionals, he contributes to a synergistic environment that fosters innovation and enhances the impact of their research endeavors.
Conclusion
Chun Hee Chung stands out as an inventive force in the field of biotechnology, particularly through his work with Ganoderma lucidum. His latest patent underscores the potential for developing novel treatments that can significantly improve patients' immune responses against tumors. As he continues to work with Il Yang Pharmaceutical Company, his contributions promise to lead to advances in medical science and therapeutic solutions, paving the way for better health outcomes.